Decision Analysis and Risk Specialty Group

Risk Assessment for Nanomaterials:
Current Developments and Trends
Full Day Continuing Education Course
http://www.cambridgepublichealth.org/events/nano_workshop.php

29 May 2007, Massachusetts Institute of Technology, Room 10-250

Organized by Igor Linkov (Society for Risk Analysis/Intertox), Mike  
Ellenbecker (Mass. Toxic Use Reduction Institute), and Sam Lipson  
(Cambridge Public Health Department)

With 300 products in use today, what information is available to  
demonstrate that nanomaterials do not pose
unnecessary risks to human and environmental health?  What areas are  
in need of EHS science?  How could risks
and environmental impacts of nanomaterials throughout the product  
life-cycle be minimized with engineering
practices to improve product safety and to avoid potential future  
litigation?  Our training course is designed to help
you navigate the ever-changing world of nanotechnology.

The day-long training course will cover a diverse range of topics  
essential for professionals in
nanotechnology and biotechnology, with nationally recognized experts  
from industry, academia, and government
leading each topic.  Participants will include government regulators,  
corporate decision makers, and scientists in the
field.  Topics will include a discussion of the current understanding  
of nanomaterial risks,  EHS state-of-the-
practice in companies involved with nanomaterials, a discussion of  
current and anticipated regulatory developments
in the field, a primer on the toxicology of nanomaterials (including  
ecotoxicological issues), and an assessment of
appropriate occupational safety and health practices associated with  
these technologies.

Participants should expect to gain an awareness of the critical  
issues in this evolving field and a set of
conceptual tools needed to make decisions and prioritize challenges  
in their own organizations.  Nanotechnology is
a broad and complex field of research and manufacturing with many  
discrete decision-points.  For example, some
decisions might be based upon an ability to predict which  
nanomaterials will have favorable chemical
characteristics and lower toxicities, to identify important knowledge  
and technology gaps, and to develop effective
communication with stakeholders and the general public.  This course  
is intended to facilitate those who must make
these decisions in an uncertain environment.

Lectures

Opening Remarks  ñ  Kim Thompson (MIT, President of the Society for  
Risk Analysis)

Nanotechnology: Current State ñ T. Earles (Office of Science and  
Technology Policy, White House)

Exposure to Nanomaterials ñ M. Ellenbecker (Massachusetts Toxic Use  
Reduction Institute)

Nanomaterial Risk Characterization ñ K. Kulinowski, International  
Council on Nanotechnology, Rice University

Ecotoxicology of Nanomaterials ñ J. Steevens (Army Corps of Engineers)

Impact through NanoProduct Life-cycle ñ J. Isaacs (Northeastern  
University)

Nanomaterials: Environmental Health and Safety ñ V. Murashov (NIOSH)

NanoSafe: Controlling Exposure in the Workplace ñ M. Hull (Luna  
Innovation) and I. Linkov (Intertox)

Nanotechnology Regulation: FDA Views ñ US FDA, TBA

Managing Nanomaterial EHS Legal Risks - A Practical Approach ñ J.  
Votaw (Wilmer and Hale)

Nano regulations at City levels: Motivation and Needs ñ S. Lipson  
(City of Cambridge)

Nano regulations at City levels: Berkeley Experience ñ J. Monica  
(Porter Wright)

Expert Understanding of Nano-Safety: A View from Canada ñ L.  
Sheremeta (National Nanotech Institute, Canada)

Nanomaterials Risk Assessment Research Strategy ñ M. Davis and J.  
Shatkin (US EPA and Cadmus)

Linking Risk Assessment and Decision Analysis for Nanotechnology ñ I.  
Linkov (Intertox Inc)

Contact Dr. Igor Linkov, at 6172250812, ilinkov**At_Symbol_Here**intertox.com

Previous post   |  Top of Page   |   Next post